Phreesia reports developments tied to its patient activation platform for healthcare providers, life sciences companies and other organizations. The company’s recurring news includes quarterly results, stakeholder letters, patient intake, outreach, education and appointment-scheduling solutions, and the scale of patient visits enabled through its digital workflows.
Company updates also cover healthcare payment capabilities, including the completed AccessOne acquisition, credit-facility refinancing, and corporate governance or workplace recognition items. Phreesia’s news flow is centered on software, payments and engagement tools used across healthcare delivery and patient interactions.
Phreesia, Inc. (NYSE: PHR) reported a revenue of $51 million for Q2 FY 2022, marking a significant 46% increase from the same quarter last year. The average number of provider clients rose by 19% to 1,987, and average revenue per client increased by 14% to $19,720. However, the company recorded a negative adjusted EBITDA of $11 million, a decline from a positive $1.2 million in Q2 FY 2021. Phreesia has raised its fiscal 2022 revenue outlook to $195-$198 million, up from $191-$194 million, but anticipates increased cash outflow due to ongoing hiring and infrastructure investments.
Summary not available.
Phreesia, Inc. (NYSE: PHR) is set to hold a conference call on September 2, 2021, at 8:30 a.m. ET to discuss its fiscal Q2 2022 financial results. A press release detailing these results will be available after the market close on September 1, 2021. The conference call can be accessed by calling (866) 211-4557 or (647) 689-6750 internationally, using conference code 7489917. Phreesia’s platform aids healthcare organizations in streamlining the patient intake process, improving both patient engagement and clinical efficiency.
Phreesia has partnered with the developers of the SEEK model to provide pediatric primary care providers with a screening tool for adverse childhood experiences (ACEs) and negative social determinants of health (SDOH). This automated questionnaire enhances pediatricians' ability to deliver comprehensive care and address family issues such as parental depression and substance use. Studies show that implementing SEEK leads to significantly lower child maltreatment incidents. The SEEK tool will improve pediatric practices by allowing private completion via mobile devices before visits, enabling informed discussions during appointments.
Phreesia has launched Appointment Accelerator, an innovative AI-driven solution designed to automatically fill cancelled appointments and enhance patient access without staff involvement. This tool reduces the average time to fill an open slot to just 5.3 minutes, significantly improving efficiency and reducing wait times by 18.5 days. Medical practices using this solution can fill an average of 15.6 appointments per provider monthly, thereby increasing patient volume and minimizing revenue loss from no-shows. This aligns with Phreesia's goal of improving the healthcare experience.
Phreesia reported a 45% year-over-year revenue increase to $48.3 million for Q1 FY2022, driven by a rise in provider clients, up 17% to 1,902. Average revenue per client also rose by 21% to $20,222. However, adjusted EBITDA fell to $0.1 million from $1.5 million last year. Cash and equivalents grew significantly to $450.7 million following a $245.8 million stock offering. The company raised its revenue guidance for FY2022 to $191-$194 million, up from $178-$186 million, despite anticipating increased cash outflow due to hiring and infrastructure investments.
Phreesia has been recognized by Modern Healthcare as one of the 2021 Best Places to Work in Healthcare, marking its fifth consecutive honor. CEO Chaim Indig expressed pride in the dedicated team that supports clients in the healthcare sector. The award honors 150 U.S. healthcare organizations that empower employees to enhance patient care, evaluated through employee surveys focusing on culture, leadership, and satisfaction. Senior VP of Human Resources, Amy VanDuyn, emphasized the importance of fostering a supportive community within their diverse, remote workforce.
Phreesia announces that David Linetsky, SVP of Life Sciences, has been recognized as one of the 2021 PM360 ELITE 100 for his transformative contributions in healthcare. Chosen from over 500 candidates, Linetsky's leadership in restructuring the Life Sciences department and launching PatientInsights has significantly impacted patient engagement. His efforts during the COVID-19 pandemic also included co-authoring reports highlighting the effects on outpatient visits. Linetsky expressed pride in his team’s work and the potential of Phreesia’s technologies.
Phreesia, Inc. (NYSE: PHR) is set to hold a conference call on June 4, 2021, at 8:30 a.m. Eastern Time to discuss its fiscal Q1 2022 financial results. The press release detailing these results will be issued after market close on June 3, 2021. The company specializes in providing healthcare organizations with a suite of applications designed to enhance patient intake processes, thereby improving clinical care and operational efficiency.
Phreesia has partnered with the Ad Council and the Alzheimer’s Association to enhance awareness of Alzheimer’s disease through targeted public service announcements. In the initial 10 weeks, nearly 90,000 patients and caregivers engaged with the campaign, with over 1,500 completing a survey. Results indicated that those exposed to the campaign were more than 25% likely to recognize Alzheimer's symptoms. Notably, 52% of engaged patients expressed intentions to discuss Alzheimer’s with their healthcare providers. The campaign aims to promote early diagnosis, crucial for better outcomes in managing the disease.